Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate

References

• Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991–8
   PubMed Web of Science ®Google Scholar
• Norlen BJ, Fritjofsson A, Gronquist L, Gunnarsson PO, Johansson SA, Plym-Forshell G. Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer. Eur Urol 1987; 13: 193–7
   PubMed Web of Science ®Google Scholar
• Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A. Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol 1988; 11(Suppl 2)S101–3
   PubMedGoogle Scholar
• Stege R, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 1989; 14: 183–8
   PubMed Web of Science ®Google Scholar
• Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol 1998; 82: 63–8
   PubMedGoogle Scholar
• Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer—Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2002; 36: 405–13
   PubMed Web of Science ®Google Scholar
• Mostofi FK. International histological classification of tumours, No. 22. Histological typing of prostate tumours. WHO, GenevaSwitzerland 1980
   Google Scholar
• UICC. TNM-classification of malignant tumours, MH Harmer, editor. 3rd edition, GenevaSwitzerland: 1978, Enlarged and revised 1982., , p. 118–121.
   Google Scholar
• Weimar C, Kraywinkel K, Rodl J, Hippe A, Harms L, Kloth A, et al. Etiology, duration, and prognosis of transient ischemic attacks: an analysis from the German Stroke Data Bank. Arch Neurol 2002; 59: 1584–8
   PubMedGoogle Scholar
• Donnelly R, Yeung JM. Management of intermittent claudication: the importance of secondary prevention. Eur J Vasc Endovasc Surg 2002; 23: 100–7
   PubMed Web of Science ®Google Scholar
• Clark TG, Murphy MF, Rothwell PM. Long term risks of stroke, myocardial infarction, and vascular death in “low risk” patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 2003; 74: 577–80
   PubMed Web of Science ®Google Scholar
• Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003; 34: 2310–22
   PubMed Web of Science ®Google Scholar
• Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96: 44–9
   PubMed Web of Science ®Google Scholar
• Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: scientific review. JAMA 2002; 288: 1388–95
   PubMed Web of Science ®Google Scholar
• Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, Prior D, et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003; 48: 81–9
   PubMed Web of Science ®Google Scholar
• Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898–904
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71–86
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Smith S, Antman E. American College of Cardiology. American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines. Part I: where do they come from?. Circulation 2003; 107: 2979–86
   PubMed Web of Science ®Google Scholar
• Alfthan O, Holsti LR. Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma. Scand J Urol Nephrol 1969; 3: 183–7
   PubMed Web of Science ®Google Scholar
• Iversen P. Carcinoma of the prostate. Response criteria. Scand J Urol Nephrol Suppl 1991; 139: 31–8
   PubMedGoogle Scholar
• Cox DR. Regression model of life tables. J R Stat Soc 1972; B34: 187–220
   Google Scholar
• Haapiainen R, Rannikko S, Alfthan O. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective cancer study. Br J Urol 1986; 58: 528–33
   PubMedGoogle Scholar
• Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R, et al. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate 1989; 14: 177–82
   PubMed Web of Science ®Google Scholar
• Henriksson P, Blomback M, Bratt G, Edhag O, Eriksson A, Vesterqvist O. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989; 6: 219–25
   PubMedGoogle Scholar
• Aro J, Haapiainen R, Rasi V, Rannikko S, Alfthan O. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients. Eur Urol 1990; 17: 161–5
   PubMed Web of Science ®Google Scholar
• Henriksson P, Blomback M, Eriksson A, Stege R, Carlstrom K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br Med J 1990; 65: 282–5
   Google Scholar
• Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolysis 1994; 5(Suppl 1)S5–11
   PubMedGoogle Scholar
• Gathof BS, Picker SM, Rojo J. Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 2004; 30: 95–103
   Google Scholar
• Kohli M, Kaushal V, Mehta P. Role of coagulation and fibrinolytic system in prostate cancer. Semin Thromb Hemost 2003; 29: 301–8
   PubMed Web of Science ®Google Scholar
• Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 1989; 63: 512–4
   PubMedGoogle Scholar
• Haapiainen R, Rannikko S, Alfthan O. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group. Br J Urol 1990; 66: 94–7
   PubMedGoogle Scholar